Added to YB: 2024-11-11
Pitch date: 2024-11-09
NVO [bullish]
Novo Nordisk A/S
-65.05%
current return
Author Info
Disruptive Analytics has 30+ years of experience as a retail investor and is now fully engaged in managing their own money. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 104.92
Price Target
N/A
Dividend
4.94%
EV/EBITDA
7.46
P/E
10.29
EV/Sales
3.74
Sector
Pharmaceuticals
Category
value
Novo Nordisk A/S - $NVO
NVO: Oversold (RSI ~30) with DKK870 FVE. CFO projects high teens 2025 sales growth. Wide moat from innovation: CagriSema, oral semaglutide, comorbidity trials. Bears exaggerate competition; bulls overestimate pricing. Pipeline strength (OASIS, SOUL, FOCUS, STRIDE) maintains leadership. Cheap at current levels.
Read full article (3 min)